These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 38853641)

  • 1. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
    Goulart H; Masarova L; Mesa R; Harrison C; Kiladjian JJ; Pemmaraju N
    Br J Haematol; 2024 Jul; 205(1):48-60. PubMed ID: 38853641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative neoplasms in adolescents and young adults.
    Amerikanou R; Lambert J; Alimam S
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101374. PubMed ID: 36333071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice.
    Lee J; Godfrey AL; Nangalia J
    Blood Rev; 2020 Jul; 42():100708. PubMed ID: 32571583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
    Coltro G; Loscocco GG; Vannucchi AM
    Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Robinson SE; Harrison CN
    Br J Haematol; 2020 May; 189(4):625-634. PubMed ID: 32150650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.
    Singh S; Kaur K; Paul D; Jain K; Singh J; Narang V; Garg B; Sood N; Dhillon B
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e569-e578. PubMed ID: 33757770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
    Büttner-Herold M; Sticht C; Wiech T; Porubsky S
    Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
    O'Sullivan J; Mead AJ
    Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
    Takenaka K
    Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of the myeloproliferative neoplasms.
    Greenfield G; McMullin MF; Mills K
    J Hematol Oncol; 2021 Jun; 14(1):103. PubMed ID: 34193229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
    Strickland M; Quek L; Psaila B
    Br J Haematol; 2022 Mar; 196(5):1149-1158. PubMed ID: 34618358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloproliferative neoplasms: young patients, current data and future considerations.
    Sobas M; Ianotto JC; Kiladjian JJ; Harrison C
    Ann Hematol; 2024 Sep; 103(9):3287-3291. PubMed ID: 39110200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and management of children, adolescents, and young adults with Philadelphia chromosome-negative myeloproliferative neoplasms].
    Sugimoto Y
    Rinsho Ketsueki; 2023; 64(10):1314-1325. PubMed ID: 37914247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphology of myeloproliferative neoplasms.
    Ng ZY; Fuller KA; Mazza-Parton A; Erber WN
    Int J Lab Hematol; 2023 Jun; 45 Suppl 2():59-70. PubMed ID: 37211431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in myeloproliferative neoplasms - their significance and clinical use.
    Schischlik F; Kralovics R
    Expert Rev Hematol; 2017 Nov; 10(11):961-973. PubMed ID: 28914569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.